We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-64.00 | -0.60% | 10,678.00 | 10,688.00 | 10,690.00 | 10,780.00 | 10,674.00 | 10,756.00 | 1,773,970 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 27.83 | 165.72B |
Date | Subject | Author | Discuss |
---|---|---|---|
23/11/2020 13:01 | BBC New seems to have got the message, now reporting today news as it should be. | hyper al | |
23/11/2020 12:41 | The AZN Oxford vaccine uses a dead (cold) virus as the Covid spike protein vector instead of the novel mRNA approach of Pfizer and Moderna. The novel mRNA vaccines are injected into muscle cells which combine the mRNA generating spike protein with the muscle cell DNA to invoke antibodies against the Covid spike protein. Your muscle cell DNA is not 'hijacked' by the dead cold virus vector approach of the AZN Oxford vaccine. The same antibodies and T cells against the Covid-19 spike protein coat are invoked by all three vaccines. | bountyhunter | |
23/11/2020 12:39 | bountyhunter Is the AZN's Oxford vaccine 'traditional technology? How is it traditional? | hyper al | |
23/11/2020 12:38 | I wonder if CNN and FOXNEWS are quoting the 90% result in the US or downplaying this tremendous result like the twisted BBC? | bountyhunter | |
23/11/2020 12:33 | bluemango - agreed - AZN's Oxford vaccine will still be required in large quantities long after the pandemic is declared 'over' by AZN from which point they can potentially make huge profits. Indeed it may be only vaccines - of which the Oxford vaccine will clearly be the market leader overall given cost, storage temp. efficacy, and it's traditional technology - that keep the pandemic status as 'over'. | bountyhunter | |
23/11/2020 12:32 | Blue.Thanks for clarifying. | coxsmn | |
23/11/2020 12:31 | BBC is nothing more than an online rag media outlet, gloom doom and all paid for by Idiot tax payers Not me though I REFUSE TO WATCH OR PAY | boxerdogz | |
23/11/2020 12:29 | Oxford Biomedica OXB has been bulking up the Oxford vaccine in parallel to the Phase III AZN trials.. | bountyhunter | |
23/11/2020 12:13 | Yes Hyper I agree, turn on Skynews and you see 90% for the regime which will obviously be used but the twisted BBC misleading say the 70% figure! Clearly the point of trials is to find the dosage regime giving the best result. Pfizer or Moderna would I'm sure have ONLY reported on the 90% result, they cannot be trusted as all about profit whereas the Oxford vaccine is no profit until the pandemic ends (however AZN choose to define that). It will be the Oxford vaccine that saves the world not the expensive difficult to distribute potentially risky Pfizer or Moderna mRNA vaccines. | bountyhunter | |
23/11/2020 12:05 | coxsmn : No. Check my post #3030. It will likely be a source of profitable income, from worldwide, for AstraZeneca for many years to come, once the pandemic is declared 'over' (which could possibly be as soon as July) | bluemango | |
23/11/2020 11:47 | bountyhunter That is exactly what I have told the BBC. BBC should take the double dose 90% figure, as the Pfizer one is double dose and people are now making false comparison, all because BBC does not know how to do unbiased reporting any more! | hyper al | |
23/11/2020 11:46 | Will AZN Covid 19 vaccine always be sold at for non profit. | coxsmn | |
23/11/2020 11:25 | That's a pump and Dump Dan | boxerdogz | |
23/11/2020 10:48 | FYI Have a look at this tiddler.. Dan X | daniel levi bmd | |
23/11/2020 10:27 | Forget the 70% average it's meaningless as of course the 90% regime will be used going forwards and has the added advantage of requiring 1.5 rather than 2 doses so the traditional Oxford vaccine will go further and also only requires fridge temp for up to 6 MTHS storage, not to mention it's 10x cheaper than the Pfizer/Moderna novel mRNA vaccines which may have as yet unknown long term side effects. | bountyhunter | |
23/11/2020 10:18 | After the MP's | boxerdogz | |
23/11/2020 10:16 | Don't forget the AZN is committed to sell the Vaccine without profit, so don't be surprised that the shares have not gone through the roof. Speculators would do better in testing shares like ODX as each person jabbed by AZN will likely need your to 4 antibody tests before and after the inoculation. That'll be billions of test kits, thank you | shavian | |
23/11/2020 10:16 | This is great news Vacinate the front line workers and the poor first | boxerdogz | |
23/11/2020 10:13 | Enough to go on for now, but they also say "More data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading". I still think as more data come on, with more placebo subjects catching Covid, the efficacy rate will increase in proportion. | bluemango | |
23/11/2020 10:05 | Results are very good - but I would fire their Director of Communications. What a disaster - a real case of shooting oneself in the foot! | benchmark | |
23/11/2020 10:04 | We need a scientific explanation of why a lower dose of this vaccine works better than a higher dose. | gwr7 | |
23/11/2020 10:02 | @careful Some good points. I live in Spain, i dont even know of anyone who has had a mild case, I dont know anybody who knows anybody who has tested positive, I cant bleve they have trashed the world economy over this, Chinese master plan. On another point, somewhat underwhelmed market re Astra, Moderna and BioNgen really stolen the thunder, Astra feels a bit day late and dollar short. | porsche1945 | |
23/11/2020 10:01 | Imagine the market reaction if it hadn't have worked. Think this will stabilise and gradually move up again as the advantages and implications sink in. Reputation-wise this will have a lasting positive impact on the company, which bodes well for the business as a whole. | bluemango | |
23/11/2020 09:57 | How many times - it wasn't 70%. It was 90% for the right dosage. | imastu pidgitaswell | |
23/11/2020 09:55 | So 131 confirmed cases in the trial (we'll assume that were probably more that were asymptomatic but I'll ignore them). Trying to work out the numbers, that gives me a figure of about 200 people exposed overall So 100 were on placebo, who were exposed and were ill 100 (statistical guess) who had the vaccine and were also exposed, 30 of whom got ill. A decent degree of efficacy. Of the 100 who had the vaccine, none were seriously ill. I think the current stats are around 2-3% get serious issues. So whilst that bit is a positive, I think we need more numbers to confirm this. Would I take this vaccine? Undoubtably yes, but I'd prefer the Moderna one. Cost/storage will make this one worthwhile. | dr biotech |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions